Articles: function.
-
Pulmonary Hypertension Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Despite the availability of specific treatment, pulmonary arterial hypertension (PAH) remains a devastating and fatal disease. Slovakia has a systemic program of PAH management. Mortality data, however, have been lacking. The aim was to describe the survival in pts with newly diagnosed PAH at a referral centre in Slovakia in the era of targeted treatment and analyse causes of death. ⋯ The following authors have nothing to disclose: Milan Luknar, Branislav Liska, Peter Lesny, Ivan Varga, Peter Solik, Eva GoncalvesovaNo Product/Research Disclosure Information.
-
Surgery Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: We report a patient in whom pleuroperitoneal communication was diagnosed following the initiation of peritoneal dialysis (PD), in whom the PD could be continued after thoracoscopic partial resection of the diaphragm. ⋯ The following authors have nothing to disclose: Ryo Takahashi, Yuuichirou TakahashiNo Product/Research Disclosure Information.
-
Critical Care CasesSESSION TYPE: Case ReportsPRESENTED ON: Saturday, March 22, 2014 at 04:15 PM - 05:15 PMPURPOSE: Treatment of Pulmonary arterial hypertension (PAH) with chronic intravenous prostanoid through a chronic tunneled catheter has been reported to be associated with bacteremia and sepsis; however bacterial endocarditis is rarely reported. Here we report a patient with idiopathic PAH receiving chronic intravenous prostacyclin that developed acute Clostridium perfringens aortic valve endocarditis. ⋯ The following authors have nothing to disclose: Amitesh Agarwal, Alex DuarteNo Product/Research Disclosure Information.
-
Transplantation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: We developed a protocol to procure human lungs from victims of cardiac arrest in an urban county in North Carolina by co-operation with Emergency Medical Services (EMS), our organ procurement organization (OPO), and our hospital, and evaluate them for transplant suitability with EVLP (XVIVO™). ⋯ Thomas Egan: Other: Received donations-in-kind (equipment and supplies) from XVIVO for this research, Shareholder: and Founder, X-In8 Biologicals Corporation, deveoping products to reduce ischemia-reperfusion injury for transplant. My spouse is paid hourly for bookkeeping of NIH-funded grants., Fiduciary position (of any organization, association, society, etc, other than ACCP: President and founder of Lung Banks of America, a 501(c)3 Corporation whose mission is to promote lung retrieval from non-heart-beating donors. I am not paid. My spouse will be paid to administer a subcontract on a NIH-funded subcontract as Sect-Treasurer., Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary John Blackwell: Other: My PI and my Department received donations-in-kind (equipment and supplies) from XVIVO for this project, Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary Lolita Forrest: Other: My PI and my Department received donations-in-kind (equipment and supplies) from XVIVO for this project, Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary William Simmons: Other: My PI and my Department received donations-in-kind (equipment and supplies) from XVIVO for this project, Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary Katherine Birchard: Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary William Funkhouser: Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary Boming Dong: Other: My PI and my Department received donations-in-kind (equipment and supplies) from XVIVO for this project, Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary Staci Beamer: Other: My PI and my Department received donations-in-kind (equipment and supplies) from XVIVO for this project Sheakar Reddy: Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary Nissa Casey: Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary The following authors have nothing to disclose: J Brent Meyers, Michael Bachman, Ginger Delario, Danielle NiedfeldtEx-vivo lung perfusion (EVLP) is not approved by the FDA in humans for transplant. EVLP of lungs retrieved after death is also not approved for use in humans. The presenter has an IDE from the FDA and UNC IRB approval to offer suitable lungs retrieved after death assessed by EVLP for transplant to consented patients.
-
Asthma Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Vocal cord dysfunction (VCD) is a syndrome characterized by glottic obstruction due to vocal cord adduction, with symptoms of wheezing and dyspnea (1). It is often mistakenly diagnosed as asthma, though the use of laryngoscopy can aid in the diagnosis, as was done in this case (2). ⋯ The following authors have nothing to disclose: Kaiser Lim, Sarah NarotzkyNo Product/Research Disclosure Information.